411,077 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 411,077 shares of the company's stock, valued at approximately $4,793,000. Raymond James Financial Inc. owned about 0.40% of Intellia Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Regeneron Pharmaceuticals Inc. acquired a new position in Intellia Therapeutics in the 4th quarter valued at approximately $43,177,000. Contrarius Group Holdings Ltd acquired a new position in shares of Intellia Therapeutics in the fourth quarter valued at $11,798,000. Trexquant Investment LP bought a new position in Intellia Therapeutics in the fourth quarter worth $7,785,000. Vanguard Group Inc. lifted its position in Intellia Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock worth $118,816,000 after purchasing an additional 562,249 shares during the period. Finally, ARK Investment Management LLC boosted its stake in Intellia Therapeutics by 2.3% during the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after buying an additional 280,946 shares in the last quarter. Institutional investors own 88.77% of the company's stock.

Analyst Ratings Changes

NTLA has been the subject of a number of analyst reports. Chardan Capital reduced their price objective on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating for the company in a report on Friday, February 28th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. Truist Financial lowered their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Citigroup raised their target price on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research report on Friday, February 28th. Finally, BMO Capital Markets decreased their price target on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a research note on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $36.68.

Intellia Therapeutics Trading Up 5.9 %

Shares of NASDAQ NTLA traded up $0.48 during midday trading on Wednesday, reaching $8.68. The company's stock had a trading volume of 2,680,457 shares, compared to its average volume of 2,396,614. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The stock has a 50 day simple moving average of $8.51 and a 200-day simple moving average of $11.68. The stock has a market capitalization of $898.53 million, a price-to-earnings ratio of -1.60 and a beta of 2.23.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.